Flutamid

When ATH:
L02BB01

Characteristic.

The antitumor agent. Nonsteroidal antiandrogen nature.

Pharmacological action.
Antiandrogens, antitumor.

Application.

Pills: palliative treatment of advanced prostate cancer (incl. with metastases) monotherapy (when performing or without orchiectomy) or in combination with GnRH agonists; treatment of locally advanced prostate cancer (T_2b — T₄). Differential diagnosis of hypogonadism in men.

Ointment: girsutizm.

Contraindications.

If ingestion: hypersensitivity, severe liver disease, kidney, Thyroid.

Outwardly (ointment): kidney disease, pregnancy.

Restrictions apply.

Cardiovascular diseases, tendency to thrombosis, Reduced liver function.

Pregnancy and breast-feeding.

Category actions result in FDA - D. (There is evidence of the risk of adverse effects of drugs on the human fetus, obtained in research or practice, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk, if the drug is needed in life-threatening situations or severe disease, when safer agents should not be used or are ineffective.)

Side effects.

Gynecomastia and / or pain in the breast, galactorrhea, fluid retention, decreased libido, impotence, nausea, vomiting, diarrhea or constipation, increase or loss of appetite, liver dysfunction and / or kidney, jaundice, insomnia, headache, paraesthesia, allergicheckie reaction, subcutaneous hemorrhage, metgemoglobinemiâ, lupus-like syndrome, suppression of spermatogenesis (long-term treatment).

When applied topically: allergic skin reactions (redness, burning sensation, rash).

Cooperation.

When the system operation may increase anticoagulant effect of warfarin (anticoagulant dose should be adjusted under the control of prothrombin time).

Overdose.

Treatment: If the patient is conscious and without spontaneous vomiting, , induce vomiting. Requires control of vital functions, simptomaticheskaya therapy. Hemodialysis and peritoneal dialysis are ineffective (due to the high degree of plasma protein binding).

Dosing and Administration.

Inside: prostate cancer - By 250 mg 3 once a day; differential diagnosis of male hypogonadism - By 10 mg / kg / day 3 reception within 3 days, with the study of daily excretion of lutropin and / or summary of gonadotropins before and during the third day of dosing. Permissible to conduct tests for 5 days, with the study of daily excretion of lutropin and total gonadotropins on the background of the fifth day of admission.

Outwardly: Ointment applied thinly, gently rubbing, in the areas of skin with hirsutism, 23 times per day; after reaching effect (2-3 Months) Ointment can be applied 1 once a day. Treatment is carried out courses lasting 6-8 months with a break 1 month.

Precautions.

In the treatment of prostate cancer need to monitor liver function (Laboratory tests should be carried out 1 once a month during the first four months and then regularly). In the case of increasing the level of liver enzymes by 2-3 times compared with the upper limit of the normal range and / or jaundice in the absence of liver metastases, the use should be discontinued flutamide. When the first symptoms of liver dysfunction, such as itching, dark urine, nausea, vomiting, persistent loss of appetite, yellowing of the skin or whites of the eyes, pain in the right upper quadrant or flu-like symptoms of unknown origin should seek medical advice immediately.

In assessing the results of the differential diagnosis of male hypogonadism, should focus on the following indicators: in healthy people under normal basal urinary gonadotropins after injection, an increase in their isolation 1,5 or more times; starting with primary hypogonadism gonadotropin excretion significantly increased, реже — нормальная, use of the drug leads to a further increase in their separation and a 1.5-2; with secondary hypogonadism initial urinary gonadotropin reduced, реже — нормальная, a substantial increase in their separation after ingestion is not observed.

Cautions.

There may be a change in color of urine from amber to yellow-green.

Cooperation